Wegovy Not Doing Anything: Why Progress Can Stall or Seem Invisible

Six weeks in, one pen down, and you're wondering if yours is broken

Picture this: you ordered your first pen on a Monday, it arrived Tuesday, you started that week. Six weeks later you're on your third box, you haven't missed a dose, and the number on the scale is almost identical to where you started. It's deflating. You've read the trial results and they mentioned 15% average weight loss. Right now, 15% feels like fiction.

The first thing to understand is what the early doses are actually doing. The semaglutide titration schedule (0.25mg for four weeks, then 0.5mg, then stepping up roughly every four weeks) is not a treatment ramp. The purpose of those lower doses is tolerability: they give your gut time to adjust so that nausea, vomiting and diarrhoea are kept manageable. Appetite suppression, the mechanism that drives weight loss, builds progressively and tends to be modest at sub-therapeutic doses. Most people reach 1.7mg or 2.4mg before they notice a consistent, significant reduction in hunger. For many, weeks one to eight are a waiting period, not a failing period.

That said, some people do notice early appetite changes even at 0.25mg. If you feel nothing at all (no nausea, no reduction in hunger, no change in how full you feel after meals) that information is worth logging and raising at your next clinical review, because it may point toward factors explored below. The full clinical profile of Wegovy covers the mechanism in more detail if you want the underlying picture.

The real reasons semaglutide can underperform

Assuming you've reached the maintenance dose and have been stable on it for several weeks, a genuine lack of response deserves more investigation than reassurance. There are well-documented reasons this happens.

The most overlooked one is calorie compensation through liquids. Wegovy reduces solid food appetite quite effectively, but it has less power over the desire for calorie-dense drinks: fruit juice, smoothies, sweetened coffee, alcohol. People who replace a smaller meal with a large oat-milk latte and a glass of wine in the evening can easily cancel the deficit the medicine created. This isn't a moral observation, it's physiology, and it matters enormously for interpreting results.

Underlying medical conditions play a role too. Untreated or undertreated hypothyroidism, polycystic ovary syndrome, and significant insulin resistance all impair the body's ability to mobilise fat even when appetite falls. If any of these are uncontrolled, the medicine is working against a current it can't overcome alone. Your prescriber may want to know whether these conditions have been recently assessed.

Medications matter. Some antidepressants, antipsychotics, corticosteroids and insulin sensitisers genuinely affect weight regulation and can blunt a GLP-1's effect. If you've started or changed a medication around the same time as Wegovy, that interaction is worth discussing explicitly.

Finally, stress and sleep deprivation raise cortisol, which drives fat retention and appetite for energy-dense foods independent of what any medicine does. Behaviours that can undermine your progress on Wegovy covers the practical side of this in more depth. The NHS's patient information for semaglutide is also useful background reading on how the medicine works and what to monitor.

When 'not working' actually means it's working differently than you expected

Weight loss is rarely linear, and scales measure more than fat. During the early weeks of any calorie-reduced diet, the body holds on to water, particularly if carbohydrate intake hasn't changed much. Muscle retained through activity also weighs more than fat lost. It is genuinely possible to lose several centimetres from your waist, notice your clothes fitting differently, and see almost no movement on the scale over a fortnight.

The experience of not losing weight on Wegovy despite apparent compliance is explored in its own page, including the research on non-responders and partial responders. The short version: about 10–15% of people in the STEP 1 trial lost less than 5% of their body weight at 68 weeks. A small group genuinely does not respond well to semaglutide. That is a clinical conversation, not a personal failure, and the answer may involve reconsidering the medicine, the dose, or whether semaglutide is the most appropriate GLP-1 for your profile, a question you can explore further if you want to understand how Wegovy and semaglutide relate to each other before that conversation. If you're curious about how costs compare between options, the context around Wegovy pricing in the UK is useful reading before making any change.

NICE guidance on semaglutide (TA875) notes that continuing treatment should be reviewed if weight loss is under 5% after six months at the maintenance dose, published guidance from NICE's appraisal of semaglutide for weight management sets that as the clinical benchmark. That marker exists precisely because the medicine doesn't work equally for everyone, and the right response is a structured review rather than either giving up or indefinitely continuing something that isn't helping.

What to do now, and when to ask for a clinical review

If you've been on Wegovy for fewer than eight weeks, or you're still stepping up through the titration schedule, the most useful thing you can do is keep a simple daily record: what you ate, how hungry you felt, any side effects, your weekly weight at the same time on the same day. That data gives a prescriber something concrete to work with, and it often reveals patterns (a particularly difficult week, a holiday, a payday treat) that explain a plateau.

Speaking of timing: holidays and busy weeks when routine falls apart are genuinely the most common culprits behind a short plateau. Missing a dose by a day or two, eating out more than usual, or skipping the walk you'd built into your week all compound each other. A single difficult week can look alarming on a chart but mean very little over a 68-week timeline.

If you've been at 2.4mg for more than 12 weeks and have lost under 5% of your starting weight, it is time for a clinical conversation. Similarly, if side effects are severe enough that you're eating very little but still not losing weight, a prescriber needs to know. At nume, every repeat is reviewed by a GPhC-registered prescriber before anything is dispensed, that review is the right moment to raise concerns about whether the treatment is working as expected. You can check your eligibility and speak to our prescribers if you'd like that conversation with clinical eyes on your specific situation. Our clinical team is also described on the site if you want to understand who reviews your case.